跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 68 条关于
“IMWG”
全部
68
临床试验
24
药物
24
机构
0
资讯
20
去年
Isatuximab Monotherapy Shows Promising Pharmacokinetics and Safety in Chinese Patients with Relapsed/Refractory Multiple Myeloma
去年
Daratumumab Seeks Approval for High-Risk Smoldering Multiple Myeloma
9个月前
FDA Approves Daratumumab for High-Risk Smoldering Multiple Myeloma Following Landmark AQUILA Trial Results
去年
Strategic Sequencing of T-Cell Therapies in Relapsed/Refractory Multiple Myeloma: Expert Guidelines
3年前
Nexcella's NXC-201 Shows Promise in Relapsed/Refractory Multiple Myeloma and AL Amyloidosis
6年前
MRD Negativity as a Surrogate Endpoint for PFS in Newly Diagnosed Multiple Myeloma
去年
Arcellx Reports Strong CAR-T Clinical Data Despite 72% Revenue Drop in Q2 2025
3年前
Nexcella Completes Pre-IND Meeting with FDA for NXC-201 in Multiple Myeloma and AL Amyloidosis
上个月
Multiple Myeloma in 2026: MRD-Guided Approval, Quadruplet Frontline Therapy, and Immunotherapy Moving Earlier
去年
Qilu Pharmaceutical's QLS32015 Shows Promise in Relapsed/Refractory Multiple Myeloma
第 1 页,共 2 页
上一页
下一页